Brent Limbaugh
Hematology & Oncology · Augusta, GANPI 1285727404
Payments from drug & device makers
Across 1,429 payments — averaging $50.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$12K
- Bristol Myers Squibb$7K
- AbbVie$7K
- Regeneron Healthcare Solutions, Inc.$6K
- Incyte Corporation$4K
- Avyxa Pharma, LLC$3K
- plus $32K from 54 others
What the payments were for
- Consulting fees$33,69747%
- Speaking & faculty fees$8,11311%
- Travel & lodging$5,1947%
- Food & beverage$24,87534%
- Education$3781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Revlimid$6,909
- Venclexta$6,570
- TAGRISSO$5,430
- LIBTAYO$5,175
- CALQUENCE$2,503
- Vonjo$2,000
- GAVRETO$1,480
- Yescarta$1,130
- Oncology$524
- BRUKINSA$450
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$301
- IMBRUVICA$165
- Oral Paclitaxel$150
- Encequidar$150
How this compares
$72,256 in reported general payments places this provider in the 75th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 52 | $646,090 |
| RevlimidLenalidomide | 36 | $562,648 |
| DopteletAvatrombopag Maleate | 22 | $410,942 |
| OrserduElacestrant Hcl | 17 | $390,519 |
| NubeqaDarolutamide | 29 | $382,862 |
| LenvimaLenvatinib Mesylate | 20 | $350,125 |
| ImbruvicaIbrutinib | 22 | $345,418 |
| XtandiEnzalutamide | 21 | $290,145 |
| CalquenceAcalabrutinib Maleate | 18 | $277,501 |
| LorbrenaLorlatinib | 11 | $220,857 |
| TagrissoOsimertinib Mesylate | 12 | $201,518 |
| TafinlarDabrafenib Mesylate | 12 | $178,300 |
| VerzenioAbemaciclib | 12 | $175,752 |
| VenclextaVenetoclax | 11 | $165,881 |
| PomalystPomalidomide | 11 | $159,469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $7,493 | $562,64836 claims |
| AstraZenecaCalquence, Tagrisso | $12,155 | $479,01930 claims |
| Stemline Therapeutics Inc.Orserdu | $314 | $390,51917 claims |
| BayerNubeqa | $429 | $382,86229 claims |
| Eisai Inc.Lenvima | $431 | $350,12520 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $368 | $345,41822 claims |
| PfizerLorbrena, Eliquis | $2,455 | $323,758144 claims |
| Astellas Pharma US IncXtandi | $507 | $290,14521 claims |
| NovartisTafinlar | $1,808 | $178,30012 claims |
| Lilly USA, LLCVerzenio | $222 | $175,75212 claims |
| AbbVieVenclexta | $7,100 | $165,88111 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,540 | $159,46911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Augusta
- Abdullah KutlarAugusta$2.9M
- Jigarkumar ParikhAugusta$2.1M
- Vamsi KotaAugusta$1.5M
- Asha NayakAugusta$1.2M
- Amany KeruakousAugusta$708K
- Mehmet BilenAtlanta$21.7M
- Steven McCuneMarietta$19.5M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.